Hung-Wen Cheng, Shun-Fa Yang, Pei-Lun Liao, Chiu-Hsian Lee, Gwo-Ping Jong
{"title":"胰高血糖素样肽-1受体激动剂对2型糖尿病患者痴呆发病率的影响：一项基于人群的纵向队列研究","authors":"Hung-Wen Cheng, Shun-Fa Yang, Pei-Lun Liao, Chiu-Hsian Lee, Gwo-Ping Jong","doi":"10.1002/dmrr.70058","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Aims</h3>\n \n <p>Type 2 diabetes mellitus (T2DM) is recognized for increasing the risk of dementia; however, conclusive evidence supporting interventions to mitigate this risk remains elusive. This study endeavours to ascertain whether the glucagon-like peptide-1 receptor agonists (GLP-1RAs) correlate with reduced incidence of dementia.</p>\n </section>\n \n <section>\n \n <h3> Materials and Methods</h3>\n \n <p>The cohort comprised individuals initiating treatment with either GLP-1RAs or non-GLP-1RAs medications between 201<span>3</span> and 2021. This study examined the association between GLP-1RAs and the risk of all-cause dementia. Propensity score-matched and Cox proportional hazard models were employed to calculate the adjusted hazard ratio (aHR) and confidence interval (CI) for the incidence of dementia.</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>Among a cohort comprising 109,778 individuals, the use of GLP-1RA demonstrated a reduced risk of dementia compared with its non-use (aHR, 0.90; 95% CI, 0.83–0.97). Subgroup analyses stratified by different diabetic complications revealed significantly lower dementia incidence rates among GLP-1RAs users than among non-GLP-1RAs users. Individuals aged ≤ 75 years demonstrated a significant protective effect within GLP-1RAs users.</p>\n </section>\n \n <section>\n \n <h3> Conclusions</h3>\n \n <p>The utilization of GLP-1 receptor agonists instead of non-GLP-1RAs medications demonstrated an association with a decreased incidence of dementia.</p>\n </section>\n </div>","PeriodicalId":11335,"journal":{"name":"Diabetes/Metabolism Research and Reviews","volume":"41 5","pages":""},"PeriodicalIF":4.6000,"publicationDate":"2025-06-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/dmrr.70058","citationCount":"0","resultStr":"{\"title\":\"Impact of Glucagon-Like Peptide-1 Receptor Agonists on the Dementia Incidence in Patients With Type 2 Diabetes Mellitus: A Population-Based Longitudinal Cohort Study\",\"authors\":\"Hung-Wen Cheng, Shun-Fa Yang, Pei-Lun Liao, Chiu-Hsian Lee, Gwo-Ping Jong\",\"doi\":\"10.1002/dmrr.70058\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div>\\n \\n \\n <section>\\n \\n <h3> Aims</h3>\\n \\n <p>Type 2 diabetes mellitus (T2DM) is recognized for increasing the risk of dementia; however, conclusive evidence supporting interventions to mitigate this risk remains elusive. This study endeavours to ascertain whether the glucagon-like peptide-1 receptor agonists (GLP-1RAs) correlate with reduced incidence of dementia.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Materials and Methods</h3>\\n \\n <p>The cohort comprised individuals initiating treatment with either GLP-1RAs or non-GLP-1RAs medications between 201<span>3</span> and 2021. This study examined the association between GLP-1RAs and the risk of all-cause dementia. Propensity score-matched and Cox proportional hazard models were employed to calculate the adjusted hazard ratio (aHR) and confidence interval (CI) for the incidence of dementia.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Results</h3>\\n \\n <p>Among a cohort comprising 109,778 individuals, the use of GLP-1RA demonstrated a reduced risk of dementia compared with its non-use (aHR, 0.90; 95% CI, 0.83–0.97). Subgroup analyses stratified by different diabetic complications revealed significantly lower dementia incidence rates among GLP-1RAs users than among non-GLP-1RAs users. Individuals aged ≤ 75 years demonstrated a significant protective effect within GLP-1RAs users.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Conclusions</h3>\\n \\n <p>The utilization of GLP-1 receptor agonists instead of non-GLP-1RAs medications demonstrated an association with a decreased incidence of dementia.</p>\\n </section>\\n </div>\",\"PeriodicalId\":11335,\"journal\":{\"name\":\"Diabetes/Metabolism Research and Reviews\",\"volume\":\"41 5\",\"pages\":\"\"},\"PeriodicalIF\":4.6000,\"publicationDate\":\"2025-06-07\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://onlinelibrary.wiley.com/doi/epdf/10.1002/dmrr.70058\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Diabetes/Metabolism Research and Reviews\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://onlinelibrary.wiley.com/doi/10.1002/dmrr.70058\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"ENDOCRINOLOGY & METABOLISM\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Diabetes/Metabolism Research and Reviews","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/dmrr.70058","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}
Impact of Glucagon-Like Peptide-1 Receptor Agonists on the Dementia Incidence in Patients With Type 2 Diabetes Mellitus: A Population-Based Longitudinal Cohort Study
Aims
Type 2 diabetes mellitus (T2DM) is recognized for increasing the risk of dementia; however, conclusive evidence supporting interventions to mitigate this risk remains elusive. This study endeavours to ascertain whether the glucagon-like peptide-1 receptor agonists (GLP-1RAs) correlate with reduced incidence of dementia.
Materials and Methods
The cohort comprised individuals initiating treatment with either GLP-1RAs or non-GLP-1RAs medications between 2013 and 2021. This study examined the association between GLP-1RAs and the risk of all-cause dementia. Propensity score-matched and Cox proportional hazard models were employed to calculate the adjusted hazard ratio (aHR) and confidence interval (CI) for the incidence of dementia.
Results
Among a cohort comprising 109,778 individuals, the use of GLP-1RA demonstrated a reduced risk of dementia compared with its non-use (aHR, 0.90; 95% CI, 0.83–0.97). Subgroup analyses stratified by different diabetic complications revealed significantly lower dementia incidence rates among GLP-1RAs users than among non-GLP-1RAs users. Individuals aged ≤ 75 years demonstrated a significant protective effect within GLP-1RAs users.
Conclusions
The utilization of GLP-1 receptor agonists instead of non-GLP-1RAs medications demonstrated an association with a decreased incidence of dementia.
期刊介绍：
Diabetes/Metabolism Research and Reviews is a premier endocrinology and metabolism journal esteemed by clinicians and researchers alike. Encompassing a wide spectrum of topics including diabetes, endocrinology, metabolism, and obesity, the journal eagerly accepts submissions ranging from clinical studies to basic and translational research, as well as reviews exploring historical progress, controversial issues, and prominent opinions in the field. Join us in advancing knowledge and understanding in the realm of diabetes and metabolism.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
